Profile data is unavailable for this security.
About the company
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
- Revenue in USD (TTM)0.00
- Net income in USD-150.28m
- Incorporated2020
- Employees90.00
- LocationHillevax Inc321 Harrison Ave, Suite 500BOSTON 02118United StatesUSA
- Phone+1 (617) 213-5054
- Fax+1 (617) 213-5054
- Websitehttps://www.hillevax.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDxHealth SA | 80.74m | -40.80m | 84.64m | 300.00 | -- | -- | -- | 1.05 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Genelux Corp | 8.00k | -27.66m | 84.96m | 23.00 | -- | 2.54 | -- | 10,619.66 | -0.9537 | -0.9537 | 0.0003 | 0.9703 | 0.0002 | -- | -- | 347.83 | -74.41 | -- | -92.15 | -- | -- | -- | -345,750.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Generation Bio Co | 18.58m | -145.47m | 88.17m | 174.00 | -- | 0.8437 | -- | 4.74 | -2.19 | -2.19 | 0.2797 | 1.56 | 0.059 | -- | 56.31 | 106,793.10 | -46.16 | -36.96 | -51.29 | -39.21 | -- | -- | -782.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Inotiv Inc | 501.06m | -99.22m | 88.69m | 1.96k | -- | 0.487 | -- | 0.177 | -3.84 | -3.84 | 19.44 | 7.00 | 0.615 | 8.12 | 6.83 | 256,297.70 | -12.11 | -23.84 | -19.28 | -29.26 | 24.93 | 29.31 | -19.70 | -33.24 | 0.2279 | -0.6234 | 0.6774 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| Quince Therapeutics Inc | 0.00 | -53.26m | 90.02m | 32.00 | -- | 2.00 | -- | -- | -1.25 | -1.25 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -50.27 | -42.72 | -52.16 | -46.06 | -- | -- | -- | -- | -- | -- | 0.249 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Hillevax Inc | 0.00 | -150.28m | 90.65m | 90.00 | -- | 0.4886 | -- | -- | -3.09 | -3.09 | 0.00 | 3.73 | 0.00 | -- | -- | 0.00 | -51.15 | -- | -54.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.68 | -- | -- | -- |
| Cabaletta Bio Inc | 0.00 | -104.16m | 91.35m | 154.00 | -- | 0.5243 | -- | -- | -2.17 | -2.17 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -55.16 | -33.76 | -60.53 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Regulus Therapeutics Inc | 0.00 | -41.63m | 91.70m | 32.00 | -- | 1.06 | -- | -- | -1.08 | -1.08 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -63.31 | -53.74 | -71.29 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.00 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Oramed Pharmaceuticals, Inc. | 0.00 | 4.47m | 93.12m | 15.00 | 23.13 | 0.5937 | 20.21 | -- | 0.0999 | 0.0999 | 0.00 | 3.89 | 0.00 | -- | -- | 0.00 | 2.22 | -- | 2.79 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Assembly Biosciences Inc | 28.33m | -40.80m | 93.56m | 65.00 | -- | 3.60 | -- | 3.30 | -7.54 | -7.54 | 5.14 | 4.09 | 0.373 | -- | -- | 435,784.60 | -53.73 | -39.69 | -79.14 | -44.03 | -- | -- | -144.05 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Annovis Bio Inc | 0.00 | -40.94m | 93.68m | 6.00 | -- | 12.77 | -- | -- | -3.76 | -3.76 | 0.00 | 0.5318 | 0.00 | -- | -- | 0.00 | -333.05 | -106.31 | -523.91 | -124.71 | -- | -- | -- | -- | -- | -3.51 | 0.00 | -- | -- | -- | -121.90 | -- | -- | -- |
| Ikena Oncology Inc | 659.00k | -59.60m | 94.50m | 18.00 | -- | 0.622 | -- | 143.41 | -1.24 | -1.24 | 0.0137 | 2.78 | 0.0036 | -- | -- | 15,325.58 | -32.72 | -29.72 | -35.50 | -34.62 | -- | -- | -9,043.85 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Nuvectis Pharma Inc | 0.00 | -19.37m | 94.67m | 13.00 | -- | 8.46 | -- | -- | -1.16 | -1.16 | 0.00 | 0.5789 | 0.00 | -- | -- | 0.00 | -97.93 | -- | -140.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Adlai Nortye Ltd (ADR) | 5.00m | -54.07m | 96.31m | 127.00 | -- | 1.80 | -- | 19.26 | -6.21 | -6.21 | 0.2465 | 1.45 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -1,081.30 | -- | -- | -- | 0.4255 | -- | -- | -- | -78.38 | -- | -- | -- |
| Karyopharm Therapeutics Inc | 148.44m | -87.48m | 97.44m | 325.00 | -- | -- | -- | 0.6565 | -0.7906 | -0.7906 | 1.17 | -1.27 | 0.6462 | 1.58 | 4.26 | 456,744.60 | -38.08 | -53.02 | -52.09 | -65.85 | 95.85 | 97.18 | -58.93 | -125.15 | 2.93 | -5.25 | 2.53 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Hillevax Inc's reporting currency: US Dollar USD
29.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 30 Sep 2024 | 4.92m | 9.88% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.96m | 3.94% |
| Franklin Advisers, Inc.as of 30 Sep 2024 | 1.95m | 3.92% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.54m | 3.10% |
| Braidwell LPas of 30 Sep 2024 | 1.06m | 2.14% |
| Balyasny Asset Management LPas of 30 Sep 2024 | 1.01m | 2.04% |
| Geode Capital Management LLCas of 30 Sep 2024 | 627.67k | 1.26% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 585.80k | 1.18% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 562.91k | 1.13% |
| Trium Capital LLPas of 30 Sep 2024 | 453.26k | 0.91% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
